Denis Moro-Sibilot1, Egbert Smit2, Javier de Castro Carpeño3, Krzysztof Lesniewski-Kmak4, Joachim Aerts5, Rosa Villatoro6, Kees Kraaij7, Karim Nacerddine8, Yulia Dyachkova9, Karen T Smith10, Kaisa Taipale11, Allicia C Girvan10, Carla Visseren-Grul7, Philipp A Schnabel12. 1. Unité d'Oncologie Thoracique-Pneumologie, CHU de Grenoble, INSERM U823 Grenoble, France. Electronic address: DMoro-Sibilot@chu-grenoble.fr. 2. Vrije Universiteit Medical Centre, Amsterdam, The Netherlands. 3. Hospital Universitario La Paz, Madrid, Spain. 4. Medical University of Gdańsk, Gdynia, Poland. 5. Amphia Hospital Breda, Rotterdam, The Netherlands; Erasmus MC, Rotterdam, The Netherlands. 6. Hospital Costa del Sol, Marbella, Spain. 7. Eli Lilly and Company, Houten, The Netherlands. 8. Eli Lilly and Company, Neuilly-sur-Seine, France. 9. Eli Lilly GmbH, Vienna, Austria. 10. Eli Lilly and Company, Indianapolis, IN, USA. 11. Oy Eli Lilly, Ab, Finland. 12. Pathologisches Institut, Universitätsklinikum, Heidelberg, Germany.
Abstract
INTRODUCTION: FRAME was a prospective observational study that captured real-world data on patients with advanced or metastatic non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapies as first-line treatment (FLT) across Europe. As previously reported, most patients observed in the study had initiated FLT with either pemetrexed, gemcitabine, vinorelbine or taxanes in combination with a platinum. Baseline patient and disease characteristics including age, performance status, and histology varied (all p<0.01) across cohorts. METHODS: Consenting adult patients initiating FLT for advanced or metastatic NSCLC with platinum-based chemotherapy, with or without a targeted agent, entered the study between April 2009 and February 2011. The choice of FLT was left to physicians' discretion per routine clinical practice. The primary objective was to evaluate overall survival (OS) across platinum-based doublet chemotherapy cohorts and key secondary objectives included the evaluation of OS in patients with different histological subtypes of NSCLC. Survival outcomes were assessed using Kaplan-Meier analysis, and unadjusted estimates are presented. RESULTS: Median OS in months was 10.3 across cohorts (n=1524), 10.7 for pemetrexed (n=569), 10.0 for gemcitabine (n=360), 9.1 for taxanes (n=295), and 10.7 for vinorelbine (n=300). For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. CONCLUSIONS: FRAME describes real-world treatment patterns and survival for patients initiating FLT for advanced or metastatic NSCLC between 2009 and 2011 across Europe.
INTRODUCTION: FRAME was a prospective observational study that captured real-world data on patients with advanced or metastatic non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapies as first-line treatment (FLT) across Europe. As previously reported, most patients observed in the study had initiated FLT with either pemetrexed, gemcitabine, vinorelbine or taxanes in combination with a platinum. Baseline patient and disease characteristics including age, performance status, and histology varied (all p<0.01) across cohorts. METHODS: Consenting adult patients initiating FLT for advanced or metastatic NSCLC with platinum-based chemotherapy, with or without a targeted agent, entered the study between April 2009 and February 2011. The choice of FLT was left to physicians' discretion per routine clinical practice. The primary objective was to evaluate overall survival (OS) across platinum-based doublet chemotherapy cohorts and key secondary objectives included the evaluation of OS in patients with different histological subtypes of NSCLC. Survival outcomes were assessed using Kaplan-Meier analysis, and unadjusted estimates are presented. RESULTS: Median OS in months was 10.3 across cohorts (n=1524), 10.7 for pemetrexed (n=569), 10.0 for gemcitabine (n=360), 9.1 for taxanes (n=295), and 10.7 for vinorelbine (n=300). For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine. CONCLUSIONS: FRAME describes real-world treatment patterns and survival for patients initiating FLT for advanced or metastatic NSCLC between 2009 and 2011 across Europe.
Authors: Maya Gottfried; Jaafar Bennouna; Igor Bondarenko; Jean-Yves Douillard; David F Heigener; Maciej Krzakowski; Anders Mellemgaard; Silvia Novello; Sergei Orlov; Yvonne Summers; Joachim von Pawel; Julia Stöhr; Rolf Kaiser; Martin Reck Journal: Target Oncol Date: 2017-08 Impact factor: 4.493
Authors: F Grossi; E Rijavec; C Genova; G Barletta; F Biello; C Maggioni; G Burrafato; C Sini; M G Dal Bello; K Meyer; J Roder; H Roder; J Grigorieva Journal: Br J Cancer Date: 2016-11-29 Impact factor: 7.640
Authors: J de Castro; P Tagliaferri; V C C de Lima; S Ng; M Thomas; A Arunachalam; X Cao; S Kothari; T Burke; H Myeong; A Grattan; D H Lee Journal: Eur J Cancer Care (Engl) Date: 2017-07-27 Impact factor: 2.520
Authors: Jeong Uk Lim; Chang Dong Yeo; Hye Seon Kang; Chan Kwon Park; Ju Sang Kim; Jin Woo Kim; Seung Joon Kim; Sang Haak Lee Journal: PLoS One Date: 2018-07-13 Impact factor: 3.240